Terms: = Skin cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
67 results:
1. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
2. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
3. The effects of ALK5 inhibition and simultaneous inhibition or activation of HIF-1α in melanoma tumor growth and angiogenesis.
Zarin B; Nedaeinia R; Laher I; Manian M; Javanmard SH
Tumour Biol; 2023; 45(1):111-126. PubMed ID: 37927290
[TBL] [Abstract] [Full Text] [Related]
4. A rapidly growing cutaneous malignant glomus tumor with a CCND3 mutation.
Kitz R; Leung O; Royer M
J Cutan Pathol; 2023 Feb; 50(2):113-117. PubMed ID: 36059094
[TBL] [Abstract] [Full Text] [Related]
5. Myeloid neoplasm with the abnormality of pdgfrb gene secondary interstitial pneumonia: A case report.
Liu G; Ouyang R; Chen P; Liu T; Zhou L; Shen C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):345-348. PubMed ID: 32386029
[TBL] [Abstract] [Full Text] [Related]
6. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract] [Full Text] [Related]
7. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
Tiago M; Capparelli C; Erkes DA; Purwin TJ; Heilman SA; Berger AC; Davies MA; Aplin AE
Br J Cancer; 2020 Mar; 122(6):789-800. PubMed ID: 31932756
[TBL] [Abstract] [Full Text] [Related]
8. Novel
Hassan M; Butler E; Wilson R; Roy A; Zheng Y; Liem P; Rakheja D; Pavlick D; Young LL; Rosenzweig M; Erlich R; Ali SM; Leavey PJ; Parsons DW; Skapek SX; Laetsch TW
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645346
[TBL] [Abstract] [Full Text] [Related]
9. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
Liao Z; Li F; Zhang C; Zhu L; Shi Y; Zhao G; Bai X; Hassan S; Liu X; Li T; Xing P; Zhao J; Zhang J; Xing R; Teng S; Yang Y; Chen K; Yang J
Exp Mol Med; 2019 Feb; 51(3):1-11. PubMed ID: 30816108
[TBL] [Abstract] [Full Text] [Related]
10. Imatinib mesylate elicits extracellular signal-related kinase (ERK) activation and enhances the survival of γ-irradiated epithelial cells.
Lee J; Ko J; Kim HJ; Im H; Kim EJ; Yi JY
Biochem Biophys Res Commun; 2018 Dec; 506(4):939-943. PubMed ID: 30396570
[TBL] [Abstract] [Full Text] [Related]
11. Imatinib Mesylate.
Waller CF
Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Fruehauf JP; El-Masry M; Osann K; Parmakhtiar B; Yamamoto M; Jakowatz JG
Cancer Chemother Pharmacol; 2018 Aug; 82(2):353-360. PubMed ID: 29943192
[TBL] [Abstract] [Full Text] [Related]
13. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract] [Full Text] [Related]
14. Local immune response in cutaneous basal cell carcinoma.
Omland SH
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975891
[TBL] [Abstract] [Full Text] [Related]
15. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib.
Castillo JM; Knol AC; Nguyen JM; Khammari A; Saint-Jean M; Dreno B
Eur J Dermatol; 2016 Oct; 26(5):452-459. PubMed ID: 27346829
[TBL] [Abstract] [Full Text] [Related]
17. Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
Antoniou EA; Koutsounas I; Damaskos C; Koutsounas S
In Vivo; 2016 09-10; 30(5):677-80. PubMed ID: 27566090
[TBL] [Abstract] [Full Text] [Related]
18. Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered treatment Vulnerabilities.
Jonas O; Oudin MJ; Kosciuk T; Whitman M; Gertler FB; Cima MJ; Flaherty KT; Langer R
Clin Cancer Res; 2016 Dec; 22(24):6031-6038. PubMed ID: 27091406
[TBL] [Abstract] [Full Text] [Related]
19. Landscape of Targeted Anti-cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/pdgfr Combination treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract] [Full Text] [Related]
20. Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.
Ilhan-Mutlu A; Siehs C; Berghoff AS; Ricken G; Widhalm G; Wagner L; Preusser M
Tumour Biol; 2016 Jan; 37(1):1173-82. PubMed ID: 26277786
[TBL] [Abstract] [Full Text] [Related]
[Next]